Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations After RSU Vesting

Immunovant CEO Peter Salzmann sold 16,163 shares of common stock on May 22, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On May 22, 2024, Peter Salzmann, the CEO of Immunovant, Inc., sold 16,163 shares of Immunovant's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of 28,204 restricted stock units (RSUs) on May 17, 2024.
• These RSUs were part of a larger grant of 451,264 RSUs awarded on August 17, 2022.
• The shares were sold at a weighted average price of $29.65, with individual transactions ranging from $29.31 to $30.02 per share.
• Following the transaction, Salzmann still beneficially owns 1,036,716 shares of Immunovant common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (sell to cover taxes) and doesn't indicate any significant positive or negative sentiment towards the company's prospects.

Positives

• The sale was not a discretionary transaction but a 'sell to cover' mandated by Immunovant to satisfy tax withholding obligations, which is a common practice.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among executives of publicly traded companies. This transaction is a routine event and doesn't necessarily indicate a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• Upon vesting, these RSUs are subject to income tax, and executives often sell a portion of the shares to cover these tax obligations.
• This 'sell to cover' strategy is a standard practice and is used by executives at companies like Regeneron, Amgen, and Biogen.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates